Shots:
- Evotec has received $6M as milestones under its iPSC-based neuroscience alliance with BMS. The milestones follow BMS’ decision to add another drug discovery project to the partnership’s portfolio
- In 2016, the companies collaborated to identify disease-modifying treatments for neurodegenerative diseases
- The partnership b/w both the companies has found several access points into neurodegenerative diseases and to-date delivered a broad portfolio targeting key disease mechanisms in neurodegeneration
Click here to read full press release/ article | Ref: Evotec | Image: Bristol Myers Squibb
The post Evotec Receives Milestones in its Neurodegeneration Collaboration with BMS first appeared on PharmaShots.
